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Background & aims: Protein-energy wasting (PEW) is increasingly becoming a clinical problem in
maintenance hemodialysis patients and guidelines call for nutritional interventions. Serum prealbumin
(transthyretin) represents a critical nutritional marker positively correlated with patient survival and
negatively correlated with morbidity. Nutritional counseling, oral supplementation as well as intra-
dialytic parenteral nutrition (IDPN) are recommended to ﬁght PEW, however clinical trials on their use
are scarce.
Methods: We conducted a prospective, multicenter, randomized, open-label, controlled, parallel-group
Phase IV clinical trial in 107 maintenance hemodialysis patients suffering from PEW to assess the
impact of IDPN on prealbumin and other biochemical and clinical parameters reﬂecting nutritional
status. Patients randomized to the intervention group received standardized nutritional counseling plus
IDPN three times weekly over 16 weeks followed by a treatment-free period of 12 weeks. The control
group received standardized nutritional counseling only. Main trial inclusion criteria included moderate
to severe malnutrition (SGA score B or C), maintenance hemodialysis therapy (3 times per week) for
more than six months, and presence of two out of the following three criteria: albumin <35 g/L, pre-
albumin <250 mg/L, phase angle alpha <4.5 assessed by bioelectrical impedance analysis (BIA).
Changes in serum prealbumin, albumin, transferrin, phase angle alpha, subjective global assessment
(SGA) score and health-related quality of life using the 12-item short form health survey (SF-12) were
investigated.
Results: IDPN signiﬁcantly increased prealbumin (p < 0.05), showing rapid rise within 16 weeks of
treatment and sustained response thereafter. In the full analysis set (n ¼ 83), 41.0% of 39 patients
receiving IDPN achieved a relevant (i.e., at least 15%) increase in prealbumin over baseline at week 4
compared to 20.5% of 44 patients in the control group. Considerably more patients with IDPN therapy
achieved an increment of prealbumin >30 mg/L at week 16 (48.7% vs. 31.8%). Prealbumin response to
IDPN therapy was more prominent in patients suffering from moderate malnutrition (SGA score B)
compared to patients with severe malnutrition (SGA score C).
Conclusions: The results of this trial demonstrate for the ﬁrst time that IDPN therapy, given three times
weekly in a 16-week short-term intervention, results in a statistically signiﬁcant and clinically relevantA, bioelectrical impedance analysis; BMI, body mass index; CHD, chronic hemodialysis; CRP, C-reactive protein; ESRD,
intradialytic parenteral nutrition; ITT, intention-to treat set; NKF KDOQI, National Kidney Foundation Kidney Disease
e; PEW, protein-energy wasting; PP, per protocol set; SES, safety evaluable set; SF-12, 12-item short form health survey;
resented as oral presentation at the 34th ESPEN Congress in Barcelona/Spain, September 2012, and as posters at the
November 2011 and the 4th DGFN Annual Meeting in Hamburg/Germany, October 2012.
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j.clnu.2015.11.016increase in mean serum prealbumin, a surrogate marker for outcome and survival in hemodialysis pa-
tients suffering from PEW, and is superior to nutritional counseling.
Clinical trial registry: www.clinicaltrials.gov (NCT00501956).
© 2015 The Authors. Published by Elsevier Ltd and European Society for Clinical Nutrition and
Metabolism. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Uremic malnutrition, also referred to as protein-energy wasting
(PEW), represents a disorder with increasing incidence in preter-
minal as well as end-stage renal disease (ESRD) patients. Preva-
lence of PEW is reported to vary between 10% and 36% in these
patients [1]. Affected patients will experience higher rates of
complications with longer disease intervals, resulting in increasing
morbidity, which ultimately leads to reduced survival in patients
dependent on dialysis [2,3]. National guidelines strongly support
nutritional intervention in all maintenance hemodialysis patients
[4]. To identify these patients the determination of serum pre-
albumin (transthyretin) and albumin as well as various nutrition-
related laboratory values can be used. Also phase angle alpha
determined by bioelectrical impedance analysis (BIA) predicts pa-
tient mortality [3].
Several attempts have been undertaken to combat this
complication in ESRD including intradialytic parenteral nutrition
(IDPN) within the overall treatment concept without, however,
exactly knowing possible beneﬁts or pitfalls. Cano et al. have
demonstrated improved body weight and serum albumin in
malnourished hemodialysis patients treated with IDPN [5]. Besides
various retrospective analyses [6,7] there is only one prospective
study that focused on long-term survival after nutritional therapy,
either with oral supplements or with IDPN [8]. The results of the
study do not support additional beneﬁt by IDPN as long as oral
nutritional supplements are given. In addition, however, it
conﬁrmed that serum prealbumin, a strong predictor of mortality
and hospitalization [9] and an indicator for morbidity andmortality
in malnourished hemodialysis patients during nutritional therapy
[10], serves as a marker for patient prognosis.
The aim of the present trial was to evaluate the effect of three
times weekly IDPN on prealbumin levels, a prognostic factor of
patient outcome as well as an indicator of the effectiveness of IDPN
treatment, and on improvement of quality of life in chronic he-
modialysis (CHD) patients suffering from PEW.2. Materials and methods
2.1. Trial design
This phase IV prospective clinical trial was designed as a
multicenter, randomized, open-label, parallel-group comparison of
nutritional counseling plus IDPN versus nutritional counseling
alone in CHD patients with moderate to severe malnutrition (IDPN-
Trial). The trial was conducted in accordance with the Declaration
of Helsinki and the ICH Harmonized Tripartite Guideline for Good
Clinical Practice (CPMP/ICH/135/95). The study protocol, the pa-
tient information and the informed consent formwere approved by
the ethics committee competent for the coordinating investigator
(“Leiter Klinische Prüfung”) according to German Drug Law before
enrollment of patients (Ethics Committee of the €Arztekammer
Nordrhein, Düsseldorf, Germany). Written informed consent was
obtained from all patients prior to any study related measures.
Standardized, valid and reliable deﬁnitions were used for adverseTA, et al., Intradialytic paren
center, open, prospective, raevent monitoring and reporting. Monitoring, data management
and statistical evaluation were done in accordance with applicable
ICH-guidelines.
The clinical trial protocol was registered on www.clinicaltrials.
gov (NCT00501956).
2.2. Patients
Adult male and female CHD patients (18 years and older) with
ESRDwere recruited into the IDPN-Trial from 13 hemodialysis units
in Germany. The ﬁrst patient entered the trial in July 2004 and the
last patient terminated the trial in February 2011. Main inclusion
criteria for patient recruitment included moderate to severe
malnutrition (SGA score B or C), maintenance hemodialysis therapy
(3 times/week) for more than six months, and presence of two out
of the following three criteria at screening: albumin <35 g/L, pre-
albumin <250 mg/L, reduced body cell mass (phase angle alpha
<4.5 assessed by BIA) (Table 1).
2.3. Treatment
All patients received nutritional counseling by an external
nutritionist once at baseline (within 4 weeks prior to randomiza-
tion). Nutritional counseling was standardized (STANDARD) and pa-
tients were maintained on their regular food behavior. After the
investigator had reviewed the inclusion and exclusion criteria,
eligible patients were consecutively randomized (in blocks of 4 per
center) in a 1:1 ratio to either the intervention group or the control
group. Randomizationwas conducted by telephone via the contract
research organization based on the generated randomization
schedule.
Patients allocated to the intervention group (STANDARD þ IDPN)
received nutritional counseling plus three IDPN administrations
per week during regular hemodialysis treatment over a period of 16
weeks (total 48 infusions). Treatment with IDPN was started in the
week after randomization because the IDPN solution was individ-
ually compounded according to ofﬁcial recommendations with
products supplied by Fresenius Kabi Deutschland GmbH (Table 2).
The high osmolality solution was administered over 4 h via an
infusion pump connected to the venous air trap chamber of the
dialysis device (maximum infusion velocity: 250 mL/h). The infu-
sion pump was supplied by the sponsor (Fresenius Kabi Deutsch-
land GmbH). The control group (STANDARD) received nutritional
counseling alone. A sham procedure was not undertaken.
2.4. Trial procedures
The individual trial durationwas 8months and comprised a pre-
randomization run-in period of maximum 1 month (4 weeks), a
study period of 4 months (16 weeks), and a follow-up period of 3
months (12 weeks) to monitor long-term response. Trial visits
included the screening visit (V1), the randomization visit (V2), four
control visits (V3eV6) at 4-week intervals during the study period,
and two visits (NV1, NV2) at 6-week intervals during the follow-up
period (Fig. 1).teral nutrition in maintenance hemodialysis patients suffering from
ndomized trial, Clinical Nutrition (2015), http://dx.doi.org/10.1016/
Table 1
Inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
 Written consent for study participation
 Hemodialysis for 6 months or longer
 At least three dialysis sessions per week
 Age 18 > years
 Minimum two of the following 3 parameters:
Albumin <35 g/L
Prealbumin (transthyretin) < 250 mg/L
reduced body cell mass: Phase angle alpha <4.5
(BIA analysis)
 Moderate to severe malnutrition: SGA level B or C
 Inadequate dialysis (Kt/V < 1.2/blood ﬂow <200 ml/min)
 Nutrition therapy with drinking water, tube feeding or parenteral nutrition for
at least four weeks prior to screening
 Chemo- or radiotherapy during the last 3 months before screening
 Corticosteroid therapy >7.5 mg/day
 Pacemaker
 Acute bacterial infection
 Acute exacerbation of an immunological disorder
 Patients with leg amputation proximal mid-thigh
 Consuming malignant diseases
 Foreseeable problems with the vascular access (within the next 8 months)
 Severe hepatic insufﬁciency
 Hepatitis and interferon therapy
 Human immunodeﬁciency virus (HIV) infection
 Severe blood clotting disorders
 Severe hypertriglyceridemia
 Difﬁculty to adjust diabetes mellitus
 Known hypersensitivity to any ingredient (e.g. levocarnitine, ﬁsh, egg or soy protein)
 Known hypersensitivity to any of the excipients
 Hypervitaminosis occurring from FrekaVit® water-soluble vitamins
 Suspicion of thiamine (vitamin B1)-hypersensitivity
 Megaloblastic anemia due to isolated vitamin B12 deﬁciency
 Zinc intoxication
 Hemochromatosis and iron utilization disorder
 Intrahepatic cholestasis
 Increased plasma levels of trace elements contained in Tracitrans® plus





Nutrients Trade name Mean amount per kg b.w.
Glucose Glucosteril® 70%a 1.35 ± 0.36 g
Aminoacids Aminoven® 15%a 0.68 ± 0.13 g
Fat Lipovenous® MCT 20%a 0.47 ± 0.13 g
Omegaven-Fresenius®a 0.07 ± 0.02 g
Vitamins FrekaVit®, water solublea 10 mL
Trace elements Tracitrans plus®a 10 mL
L-Carnitine Nefrocarnit®b 1 g
Total energy 13.59 ± 3.27 kcal
Non-protein derived energy 10.81 ± 2.83 kcal
Volume 10.29 ± 3.96 mL
b.w. ¼ body weight.
a Manufactured by Fresenius Kabi Deutschland GmbH, Bad Homburg, Germany.
b Manufactured by Medice Pharma GmbH, Iserlohn, Germany.
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All blood samples were drawn prior to dialysis sessions. The
following serum parameters were analyzed in a central laboratory
at each study visit: prealbumin (transthyretin), albumin, transferrin
(all by immunonephelometry), protein catabolic rate (PCR) and
formal urea kinetics (Kt/V by Abbas et al. [11]), ferritin, folic acid,
and vitamin B12. Routine laboratory for hematology (hemoglobin,Fig. 1. Study design. Time schedule of the IDPN-trial. A 4-week screening period was fo
intervention group (no IDPN administration in the control group) and a 12-week follow-up
Please cite this article in press as: Marsen TA, et al., Intradialytic parent
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j.clnu.2015.11.016hematocrit, erythrocytes, leukocytes, platelet count, differential
blood count, C-reactive protein (CRP), blood glucose, glycated he-
moglobin), high-/low-density lipoprotein cholesterol, triglycerides,
alanine aminotransferase, aspartate aminotransferase, urea, creat-
inine, sodium, potassium, calcium, phosphate, total protein and
protein electrophoresis) and coagulation testing (prothrombin time
and partial thromboplastin time) were done in each center's local
laboratory at each visit except visits V3 and V5.llowed by a 16-week study period with IDPN administration 3 times weekly in the
observation period.
eral nutrition in maintenance hemodialysis patients suffering from
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Nutritional status parameters monitored during the clinical trial
included body weight, body mass index (BMI), biochemical
markers (serum albumin and transferrin), SGA score and phase
angle alpha. The BMI was calculated dividing weight (kg) by height
squared (m2). Patients were classiﬁed into three BMI cohorts: BMI
<20.0 kg/m2 (underweight), 20.0e25.0 kg/m2 (normal weight), and
>25 kg/m2 (overweight).
Phase angle alphawas determined by an external nutritionist on
the day of the ﬁrst dialysis session after weekends (30 min after
dialysis and after reaching dry weight, in resting position as hand-
to-foot measurement) using BIA (DATA Input GmbH, Darmstadt,
Germany).
2.7. Health status
The SF-12 questionnaire was used as patient-reported outcome
measure to compare health status at baseline and change during
the study period and follow-up [12].
2.8. Outcome measures
2.8.1. Efﬁcacy
Primary efﬁcacy endpoint was the change in serum prealbumin
(transthyretin) from baseline (V2/week 0) to end of study period
(V6/week 16).
Secondary endpoints for the evaluation of efﬁcacy of treatment
on nutritional status were time to a relevant increase (>15%) in
prealbumin, increase in phase angle alpha (BIA) of at least 0.5,
improvement of SGA by one score (i.e., from C to B or from B to A),
increase in parameters of proteinmetabolism (albumin, transferrin,
PCR), and improvement in health-related quality of life (SF-12).
2.8.2. Tolerability
Tolerability criteria were frequency and severity of adverse
events (AEs), change in routine laboratory parameters (hematology,
clinical chemistry, coagulation) and change in vital signs (blood
pressure, pulse rate).
2.9. Statistics
2.9.1. Sample size calculation
Calculation of statistical power was established for the primary
endpoint. Based on an effect size of 0.7, a type-I error rate of 5%
(two-sided) and a power of 80%, the minimum sample size was
calculated to be 32 patients per trial arm in order to reach statistical
signiﬁcance. Assuming a rate of 15% non-evaluable patients due to
dropout, a total of 76 enrolled patients were needed. According to a
protocol amendment, an interim analysis was conducted to prove
the pre-requisites of primary endpoint hypothesis and the resulting
sample size. Due to unexpected high rate of screening failures and
patients who terminated prematurely (dropouts), the sample size
was increased to 140 patients.
2.9.2. Analysis sets
The safety evaluable set (SES) included all randomized patients
with available data on safety and tolerability. The intention-to-treat
set (ITT) included all randomized patients who had a baseline
measurement as well as at least one post-baseline measurement of
the primary endpoint parameter. The full analysis set (FAS) included
all randomized patients who had at least one measurement of the
primaryendpoint parameter atweek8 (V4) or later. Theper protocol
set (PP) included all FAS patients (including dropouts) who did not
havemajor protocol deviations thatmight have affected the primaryPlease cite this article in press as: Marsen TA, et al., Intradialytic paren
protein-energy wasting. Results of a multicenter, open, prospective, ra
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IPDN infusion bags within the past 8 weeks.2.9.3. Statistical analyses
Statistical evaluationwas performed using the ITT approach. For
detailed analysis, the full analysis set (FAS) was used since changes
of the primary endpoint were not expected to appear as early as 8
weeks after the start of intervention (V4).
Missing efﬁcacy data were imputed by the “last observation
carried forward” (LOCF) method in the ITT, FAS, and PP except
where baseline data for visit V2 were missing.
The analysis of the primary endpoint was a conﬁrmatory anal-
ysis in the FAS using a two-step adaptive control design [13]. Sec-
ondary endpoints were analyzed descriptively for the study period
(difference V6eV2) and for follow-up (NV1 þ NV2). Statistical
calculation was performed by t-test, Wilcoxon test and Chi-square
test with an alpha-level (type-I error rate) of 5% (two-sided) or 2.5%
(one-sided).
Additionally, a per protocol analysis was done for the primary
endpoint and an analysis of covariance (ANCOVA) with study center
as primary effect and the baseline prealbumin value at visit V2 as a
covariate.3. Results
3.1. Patient disposition and baseline characteristics
Among 140 patients screened for eligibility, 107 patients were
enrolled and 33 patients were excluded for not meeting the entry
criteria (screening failures). 53 patients (49.5% of 107) were ran-
domized to the intervention group (STANDARD þ IDPN) and 54 pa-
tients (50.5%) to the control group (STANDARD).
32 (60.4%) out of 53 patients in the intervention group and 47
(87.0%) out of 54 patients in the control group completed all trial
visits. 28 patients terminated the trial prematurely (dropouts).
Reasons for dropout were death (11 patients), occurrence of
adverse events, a longer hospital stay, lack of efﬁcacy, loss to follow-
up, need for IDPN treatment in the control group, and withdrawal
of consent (Fig. 2).
Major protocol deviations were identiﬁed in 30 out of 107 pa-
tients (19/53 patients in the intervention group and 11/54 patients
in the control group). Major protocol deviations included missing
post-baseline data, missing primary endpoint data, use of not
permitted concomitant medication, not permitted concomitant
disease, and poor compliance with IDPN use in the intervention
group. Five out of 107 patients were excluded from all safety and
efﬁcacy analyses due to missing post-baseline data (Fig. 2). Further
12 patients were excluded from ITT analyses because they had no
baseline or post-baseline results for the primary endpoint param-
eter prealbumin. Seven out of 90 patients with efﬁcacy data were
not valid for the analysis in the FAS because of a missing pre-
albumin value at week 8/V4. A total of 77 patients had no major
protocol deviations and were included in the PP analyses.
Table 3 provides demographics as well as clinical baseline
characteristics for the 83 malnourished ESRD patients included in
the FAS (age range: 40.7e92.8 years) All were white Caucasians,
53.0% were females. Most patients were long-term dialysis
dependent. The median duration of hemodialysis at the time of
enrollment was 38.9 months. 76% out of 83 patients had moderate
(SGA score B) and 24% had severe (SGA score C) malnutrition. There
was no difference in mean baseline parameters between patients
receiving nutritional counseling plus IDPN (STANDARD þ IDPN) and
those who received nutritional counseling alone (STANDARD) except
phase angle alpha (p ¼ 0.0437; Table 3).teral nutrition in maintenance hemodialysis patients suffering from
ndomized trial, Clinical Nutrition (2015), http://dx.doi.org/10.1016/
Fig. 2. Patient disposition.
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Treatment compliance (onlyapplicable for the interventiongroup)
was calculated based on the residual volume left in the infusion bags
and the adherence to three times weekly administration of the indi-
vidually composed IDPN solution frombaseline (week 0/V2) to end of
study period (week 16/V6). In the 39 patients receiving IDPN (FAS),
the mean compliance with IDPN use was 99% (range: 72e100%).
3.3. Efﬁcacy results
3.3.1. Prealbumin
Compared with baseline values, the mean increase in serum
prealbumin (transthyretin) from baseline to week 16 (V6) [primaryPlease cite this article in press as: Marsen TA, et al., Intradialytic parent
protein-energy wasting. Results of a multicenter, open, prospective, ra
j.clnu.2015.11.016endpoint] was 26.31 mg/L (±58.66 mg/L) in the 39 patients
receiving IDPN (intervention group) compared with a decrease
of 1.84 mg/dL (±49.35 mg/L) in the 44 patients of the control
group (FAS) (Table 4).
Patients in the intervention group had a sustained prealbumin
response to IDPN therapy lasting 6weeks after therapy had stopped
(change from baseline: 30.74 ± 58.06 mg/L at week 22/NV1), fol-
lowed by a slow decline at week 12 post intervention (change from
baseline: 15.08 ± 59.55 mg/L at week 28/NV2), while in the control
group the mean prealbumin levels remained unchanged from
baseline (1.44 ± 50.52 mg/L at week 22/NV1; 0.10 ± 56.63 mg/L at
week 28/NV2) (Fig. 3).
The advantage of nutritional counseling plus three times weekly
IDPN therapy (STANDARD þ IDPN) over nutritional counseling aloneeral nutrition in maintenance hemodialysis patients suffering from
ndomized trial, Clinical Nutrition (2015), http://dx.doi.org/10.1016/
Table 3
Demographics and clinical baseline characteristics (FAS, n ¼ 83).
Variable Unit Valid patients
(Intervention/Control)
Statistic Intervention group
“IDPN þ Standard” (n ¼ 39, 100%)
Control group
“Standard” (n ¼ 44, 100%)
p Value
Age years 39/44 Mean/SD 73.3 ± 11.8 75.0 ± 8.48 A)0.8089
Gender 39/44 C)0.8860
Females n (%) 21 (53.8) 23 (52.3%)
Males n (%) 18 (46.2) 21 (47.7%)
Body mass index (BMI) kg/m2 39/44 Mean/SD 22.3 ± 3.69 22.8 ± 3.54 B)0.4982
Dialysis dependency months 39/44 Median 37.12 39.06 A)0.8660
Phase angle alpha degree () 39/43 Mean/SD 3.81 ± 0.75 3.48 ± 0.68 B)0.0437
Prealbumin (transthyretin) mg/L 39/44 Mean/SD 209.49 ± 62.16 225.68 ± 60.52 B)0.2331
Albumin g/L 39/44 Mean/SD 33.98 ± 4.85 34.77 ± 5.09 B)0.4752
Transferrin g/L 38/43 Mean/SD 1.50 ± 0.45 1.47 ± 0.43 B)0.7887
Protein catabolic rate (PCR) g/kg b.w./day 30/36 Mean/SD 0.74 ± 0.22 0.78 ± 0.24 B)0.5391
C-reactive protein (CRP) mg/L 37/39 Mean/SD 23.54 ± 27.85 25.40 ± 37.03 B)0.8060
Health-related quality of life (SF-12) Score points 32/40 Mean/SD 26.28 ± 8.58 27.30 ± 8.32 B)0.6123
Subjective global assessment (SGA) 39/44
Grade A (good nutrition) n (%) Not included
Grade B (moderate malnutrition) n (%) 31 (79.5%) 32 (72.7%) C)0.4723
Grade C (severe malnutrition) n (%) 8 (20.5%) 12 (27.3%)
b.w. ¼ body weight; SD ¼ standard deviation.
A) Wilcoxon Two-Sample test (two-sided); B) t-test, pooled; C) Chi-square test.
The SF-score ranges from 0 to 100, where a zero score indicates the lowest level of health and 100 indicates the highest level of health.(STANDARD) on serum prealbumin was statistically signiﬁcant at week
16 (p¼ 0.0200) and week 22 (p¼ 0.0412). These ﬁndings weremore
pronounced in the per protocol set (PP; p ¼ 0.0116 at week 16/V6).
Subgroup analysis showed that prealbumin response to IDPN
therapy was more prominent in patients suffering from moderateTable 4






Week 16 (V6) 39
Difference V6eV2 39
Patients who achieved a >15% increase from baseline at week 4/V3:
Baseline (V2) 16








Week 16 (V6) 38
Difference V6eV2 38
Protein catabolic rate (PCR) [g/kg b.w./day]
Baseline (V2) 30
Week 16 (V6) 28
Difference V6eV2 22
Health-related quality of life (SF-12) [score points]
Baseline (V2) 32
Week 16 (V6) 26
Difference V6eV2 (LOCF) 31
Phase angle alpha [degree]
Baseline (V2) 39
Week 16 (V6) 38
Difference V6eV2 38
n
Increase in phase angle alpha of at least 0.5* 39
Subjective global assessment (SGA)
Improved SGA score by one grade (from C to A or from B to A)* 39
b.w. ¼ body weight; SD ¼ standard deviation; LOCF ¼ last observation carried forward; n
Chi-square test.
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j.clnu.2015.11.016malnutrition (SGA score B) compared to patients with severe
malnutrition (SGA score C) who had insigniﬁcant increases in mean
prealbumin levels and a shorter sustained response after therapy
had stopped (Fig. 4).¼ 83).
oup “IDPN þ STANDARD” Control group “STANDARD” p Value
Mean/SD/ n Mean/SD
209.49 ± 62.16 44 225.68 ± 60.52
235.80 ± 79.31 44 223.84 ± 67.28
26.31 ± 58.66 44 1.84 ± 49.35 A0.0200
194.81 ± 70.02 9 206.89 ± 37.65
264.13 ± 74.07 9 266.44 ± 42.35
69.31 ± 31.02 9 59.56 ± 17.52 n.c.
33.98 ± 4.85 44 34.77 ± 5.09
32.52 ± 6.31 44 34.94 ± 5.19
1.46 ± 4.64 44 0.17 ± 3.98 A0.0873
1.50 ± 0.45 43 1.47 ± 0.43
1.48 ± 0.44 43 1.51 ± 0.38
0.02 ± 0.26 43 0.04 ± 0.20 A0.2777
0.74 ± 0.22 36 0.78 ± 0.24
0.74 ± 0.19 36 0.77 ± 0.16
0.02 ± 0.19 29 0.02 ± 0.22 A0.9864
26.28 ± 8.58 40 27.30 ± 8.32
25.38 ± 8.79 34 26.76 ± 7.32
2.74 ± 8.98 38 0.34 ± 7.18 A0.1175
3.81 ± 0.75 43 3.48 ± 0.68
3.83 ± 0.95 44 3.60 ± 0.90
0.01 ± 0.81 43 0.12 ± 0.63 A0.4733
Patients n Patients
12 (30.8%) 44 9 (20.5%) B0.2751
8 (20.5%) 44 6 (13.6%) B0.4037
.c. ¼ not calculated; * cumulative number of patients up to V6; A: t-Test, pooled; B:
teral nutrition in maintenance hemodialysis patients suffering from
ndomized trial, Clinical Nutrition (2015), http://dx.doi.org/10.1016/
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reached for the ﬁrst time at week 4 (V3), which was the ﬁrst post-
baseline assessment. The proportion of patients who achieved a
relevant (>15%) increase at week 4 (V3) was twice as high in the
intervention group compared to the control group (41.0% vs. 20.5%;
chi-square test: p ¼ 0.0415). Both groups who achieved the relevant
(>15%) increase revealed similar prealbumin changes. The 16 pa-
tients (41.0% of 39) in the intervention had a mean prealbumin
increment from baseline of 69.31 ± 31.02 mg/L compared with
59.56 ± 17.52 mg/L achieved by the 9 patients (20.5% of 44) in the
control group (Table 4). The percentage of patients deﬁned as having
a positive response to IDPN therapy (i.e., an increase in prealbumin
30 mg/L) was higher in the intervention group compared with the
control group (48.7% vs. 31.8% at week 16/V6; p ¼ 0.1164; FAS).
3.3.2. Albumin
A small post-baseline decline in mean serum albumin levels of
maximum 1.46 g/L ± 4.64 g/L (baseline: 33.98 ± 4.85 g/L) at week
16/V6 was observed in the intervention group. No other nutritional
protein demonstrated similar changes (Table 4). In the control
group, mean serum albumin levels showed both small increases
and decreases but decreases were less than in the intervention
group. The ﬁnding prompted further investigation on possible
correlation between the positive acute phase reactant CRP and al-
bumin, a negative acute-phase reactant. There was a strong nega-
tive linear relationship between CRP and albumin values in the
intervention group for reasons unknown (Fig. 5).
3.3.3. Other biochemical and clinical parameters of nutritional
status
Table 4 shows the changes from baseline at week 16/V6 (end of
study period) in albumin, transferrin, PCR, phase angle alpha, SGAFig. 3. Change from baseline in mean serum prealbumin (transthyretin) over time in the
n ¼ 83). Changes from baseline (V2) in mean serum prealbumin during 3 times weekly IDPN
in the follow-up period (NV1 ¼week 22, NV2 ¼week 28) compared to the untreated control
the intervention group (FAS, n ¼ 39) at week 16 (V6). The treatment effect was maintained 6
but mean prealbumin values were still well above those measured in the control group (FA
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niﬁcant or clinically important differences in the measured sec-
ondary study outcomes for either treatment.
The effectiveness of the therapy could be veriﬁed on the basis of
changes inmean triglyceride andmean fasting blood glucose levels,
which demonstrated increments for triglycerides (from baseline
140.03 ± 60.62 mg/dL to 193.17 ± 86.54 mg/dL at V6) while glucose
remained unchanged (113.35 ± 30.54 at baseline and
114.43 ± 47.86 mg/dL at V6) in the intervention group. Controls did
not improve for either parameter (triglycerides:
156.69 ± 103.68 mg/dL at baseline and 164.15 ± 97.07 mg/dL at V6;
glucose: 114.87 ± 54.07 at baseline and 117.01 ± 64.49mg/dL at V6).
3.4. Safety results
IDPN was administered without acute side effects during
application. The overall occurrence of adverse events (AEs) in the
SESwas higher in the 51 patients receiving the IDPN solution (78.4%
of 51 patients reporting 147 AEs), relative to the 51 untreated pa-
tients in the control group (58.8% of 51 patients reporting 122 AEs).
Most AEs were of mild or moderate intensity (70.3% of total 269
AEs). A proportion of 28.6% were recurrent events. Gastrointestinal
disorders were reported most commonly, followed by infections/
infestations (Table 5). Infections occurred more frequently in the
control group (40.9%, n ¼ 18, FAS) compared to the intervention
group (35.9%, n ¼ 14, FAS) during the observation period. Hospi-
talization occurred more frequently in the intervention group
(59.0%, n ¼ 23, FAS) compared to the control group (43.2%, n ¼ 19,
FAS). The descriptively performed Chi-square test showed no sig-
niﬁcant difference in the incidence of infections and hospitalization
between both groups during the course of the trial (infections:
p ¼ 0.6397, hospitalization p ¼ 0.1509).intervention group (STANDARD þ IDPN) compared to the control group (STANDARD) (FAS,
treatment over 16 weeks (V3 ¼week 4, V4 ¼week 8, V5 ¼week 12, V6 ¼week 16) and
group. The difference between treatment groups was statistically signiﬁcant in favor of
weeks after stop of IPDN treatment (NV1) and declined in the following 6 weeks (NV2),
S, n ¼ 44).
eral nutrition in maintenance hemodialysis patients suffering from
ndomized trial, Clinical Nutrition (2015), http://dx.doi.org/10.1016/
T.A. Marsen et al. / Clinical Nutrition xxx (2015) 1e118AEs considered as related to IDPN therapy did not exceed 5.44%
of all AEs reported and were mild to moderate hyperglycemia (2
events), moderate metabolic decompensation of pre-existing dia-
betes mellitus (1 event), muscle cramps during hemodialysis (2
events), moderate colitis (1 event), and moderate vomiting andFig. 4. Superior prealbumin response to IDPN in patients with moderate malnutrition (SGA-B
mean serum prealbumin during 3 times weekly IDPN treatment over 16 weeks (V3 ¼week 4
22, NV2 ¼week 28) compared to the untreated control group separately for patients with m
in the control group) and severe malnutrition (SGA grade C: n ¼ 20, n ¼ 8 in the interventio
groups was statistically signiﬁcant in moderately (SGA-B) malnourished patients at wee
malnourished patients.
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j.clnu.2015.11.016diarrhea (2 events). Seven patients in the intervention group (13.7%
of 51, SES) experienced at least one AE leading to discontinuation of
IDPN therapy.
A total of 21 patients with general poor health status died during
the trial, 14 patients in the intervention group and 7 patients in the) compared to severe malnutrition (SGA-C) (FAS, n¼ 83). Changes from baseline (V2) in
, V4 ¼ week 8, V5 ¼ week 12, V6 ¼ week 16) and in the follow-up period (NV1 ¼ week
oderate malnutrition (SGA grade B: n ¼ 63, n ¼ 31 in the intervention group and n ¼ 32
n group and n ¼ 12 in the control group) at baseline. The difference between treatment
k 16 (V6) and week 22 (NV1) and not statistically signiﬁcant in severely (SGA-C)
teral nutrition in maintenance hemodialysis patients suffering from
ndomized trial, Clinical Nutrition (2015), http://dx.doi.org/10.1016/
Fig. 5. Relationship between CRP and albumin. Regression analysis to explore the
relationship between C-reactive protein (CRP) values (determined as V5eV1) and al-
bumin values (determined as V6eV2). Data from 61 out of 83 FAS patients were
analyzed. The points fall close to the line, which indicates that there is a strong
negative relationship between the two variables.
T.A. Marsen et al. / Clinical Nutrition xxx (2015) 1e11 9control group. The analysis of deaths showed no relationship be-
tween the administration of IDPN and the occurrence of serious AEs
with fatal outcome except for metabolic decompensation of pre-
existing diabetes mellitus reported for 1 patient.4. Discussion
The present trial demonstrates for the ﬁrst time that pre-
albumin, which serves as a surrogate parameter for outcome and
survival in malnourished hemodialysis patients, can be effectively
improved by short-term IDPN. Prealbumin has been shown to best
reﬂect nutritional status [14]. Increased prealbumin predicts
improved survival and is an accepted positive marker for patient
prognosis [8]. The present trial demonstrates signiﬁcantly
improved prealbumin levels as early as 16 weeks after starting
treatment with IDPN and reveals sustained response during a
treatment-free follow-up period of 12 weeks. Also the number of
patients who achieved a relevant (i.e., at least 15% respective
>30 mg/dL) increase in prealbumin is improved after treatment
with IDPN. Taken together, these results clearly demonstrate the
beneﬁcial effects of employing IDPN three times weekly in selected
patients. Given the assumption that improvements of prealbuminTable 5
Adverse events (%) according to system organ classes (SOC), SES.
MedDRA system organ classes IDPN group (n
Total adverse events 147 (100%)
Events (%)
General disorders and administration site conditions 4.8
Eye disorders 0.7
Surgical and medical procedures 5.4
Endocrine disorders 0
Skin and subcutaneous tissue disorders 4.1
Respiratory, thoracic and mediastinal disorders 2.0
Renal and urinary disorders 0.7
Gastrointestinal disorders 16.3
Nervous system disorders 10.2
Ear and labyrinth disorders 0
Vascular disorders 6.8
Neoplasms benign, malignant, and unspeciﬁc 4.1
Cardiac disorders 4.1
Infections and infestations 14.3
Hepatobiliary disorders 0.7
Psychiatric disorders 0.7
Musculoskeletal and connective tissue disorders 2.7
Metabolism and nutrition disorders 2.7
Injury, poisoning and procedural complications 16.3
Investigations 3.4
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j.clnu.2015.11.016levels may best reﬂect nutritional status and patient survival, the
trial was able to show that an intervention of 16 weeks with IDPN
treatment signiﬁcantly increases this crucial parameter in a he-
modialysis population suffering from PEW. Further long-term
evaluations are recommended to substantiate the clinical impact
of the IDPN-Trial on outcome and survival in hemodialysis
patients.
The trial population was recruited from the general German
dialysis population, although the average age was higher than re-
ported [15]. This can be explained by the fact that malnutrition is
not an early complication in this population, but occurs late and
after several years of dialysis. In the present trial, the majority of
patients (75.9% of 83; FAS) was graded as being moderately
malnourished (SGA score B), and the minority (24.1% of patients)
was severely malnourished (SGA score C). However, this small
proportion, although responding to IDPN, shows only minor to no
sustained response after discontinuation of IDPN. We assume that
it needs more than IDPN to obtain this effect, which may have been
more effectively triggered in SGA-B malnourished patients, and
that short term intervention is only a start-up, but has to be
maintained by own means, i.e. improved nutritional behavior as
well as modiﬁed life circumstances. This deﬁnitively is neither the
aim nor a target for IDPN and may lead to the conclusion that an
intervention should be initiated as early as possible in order to
compensate for PEW. On the other hand, it may indicate that IDPN
is an insufﬁciently weak intervention to recompensate patients
with severemalnutrition (SGA score C) and that further therapeutic
measures should be employed. Interventions with anabolic hor-
mones, corticosteroids or growth hormone therapy in addition to
IDPN have been investigated with promising results [16,17], and
combination of more than one therapy may be inevitable.
The trial was powered to detect signiﬁcant changes in pre-
albumin by IDPN treatment. The hypothesis was proven by the
patient number investigated. The non-signiﬁcant results of sec-
ondary endpoints is not limiting the conclusion of the trial as the
small sample size does not provide appropriate statistical power to
detect statistical signiﬁcant differences in these secondary end-
points. Albumin increments during the interventionwere not seen;
other secondary outcome parameters failed to demonstrate
changes during IDPN. This was mainly due to the fact that the trial
was not powered to distinguish these changes and was too short in
duration, so that albumin with a half-life of 20 days could not¼ 51) Control group (n ¼ 51) Total (n ¼ 102)
122 (100%) 269 (100%)
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evaluate an insigniﬁcant yet untypical decrease in albumin during
treatment, which revealed a possible inverse correlation with CRP
as confounding factor. CRP increments occurred as early as 8 weeks
and peaked at 12 weeks. However, at the end of the intervention
period (week 16), the CRP elevations returned to normal baseline
levels. The reasons for this behavior remain unclear. The fact that
untreated patients in the control groupwere also affected, had even
higher incidences of infection and that a sham procedure was not
employed, rules out IDPN-associated effects. Incipient septic com-
plications associated with the infusion procedure are not supported
by trial data. Therefore, we speculate on activation of cytokines,
such as interleukin-6 (IL-6), which has been reported to be asso-
ciated with acute-phase proteins during hemodialysis [18].
In the present trial population, the drop-out rate (26.2% of 107
patients randomized) was not higher than generally reported [19].
In the trial, they were, however, caused in particular by a long list of
exclusion criteria, especially by hospitalizationwith interruption of
IDPN for more than 3 applications. Hospitalization rates did not
occur conspicuously high in a group. Fatal adverse events are
mainly caused by cardiac failure, vascular and septic complications,
which are not different from the general dialysis population
[14,20,21]. Co-morbidities in the dialysis population are the main
factors which determine mortality. Malnutrition is correlated with
cardiac death in end stage renal disease [22,23]. The majority of
deaths in the present trial occurred in patients suffering from se-
vere malnutrition (SGA score C) and were related to pre-existing
severe cardiac and vascular diseases, while one patient died from
septic complications and one patient following a hip fracture. All
but two patients died during hospitalization and after having dis-
continued IDPN for a minimum of 11e26 days, thus making a
relationship to IPDN therapy unlikely.
The present trial provides results supporting as well as con-
trasting the FineS Trial published by Cano et al. [8] which identiﬁed
prealbumin as a marker of nutritional status and survival in hemo-
dialysis patients. Wewould like to extend this statement further and
claim that prealbumin is the critical marker to also predict clinical
response to IDPN. Cano et al. reported no beneﬁt by IDPN over oral
supplementation and postulated that nutritional markers are
improved independent of the route of administration of nutritional
supplementation as long as the targets for dietary protein and en-
ergy intake according to the guidelines of the National Kidney
Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI)
are achieved. Albeit the fact that a direct comparison of IDPN and oral
supplements was not performed, this would imply that oral nutri-
tional supplementation is equally effective as IDPN when oral intake
is possible. However, the FineS Trial lacks a consistent oral or intra-
venous control group. The fact that oral supplements were manda-
tory in the intervention arm as well, cannot support inferiority of
IDPN treatment over oral supplementation. The present trial how-
ever, although not reporting spontaneous oral nutrient uptake,
clearly distinguished between oral and parenteral treatment mo-
dalities and demonstrated the superiority of IDPN treatment over
non-interventional proceedings.
In conclusion, IDPN is a beneﬁcial therapeutic option in hemo-
dialysis patients suffering from PEW and can be employed in this
population with encouraging results. A reasonable approach to
identify patients requiring therapy should always include moni-
toring of prealbumin as marker of nutritional status. IDPN should
be started in conditions not worse than SGA-B (moderate malnu-
trition) in order to improve nutritional status over longer periods
and to improve survival in malnourished hemodialysis patients.
Response to IDPN can be monitored by using prealbumin in-
crements within weeks. Patients responding to IDPN justify further
repetitive treatment episodes. Whether IDPN is equally effective,Please cite this article in press as: Marsen TA, et al., Intradialytic paren
protein-energy wasting. Results of a multicenter, open, prospective, ra
j.clnu.2015.11.016superior or inferior to oral nutritional supplementation needs
further investigation.
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